Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant for Vasomotor Symptoms in Breast Cancer Survivors
NCT06917313Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant with Placebo (2 arms). Primary endpoint: Frequency of moderate/severe vasomotor symptoms at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06917313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917313.